Vorasidenib - Latest Advances

Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases.

Journal: Neuro-oncology practice

Published: March 09, 2026

IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis.

Journal: bioRxiv : the preprint server for biology

Published: February 12, 2026

Multidisciplinary consensus recommendations for the management of IDH-mutant grade 2 gliomas in Spain: a Delphi study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 05, 2026

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Journal: Journal of neuro-oncology

Published: January 08, 2026

Reproductive health considerations for IDH-mutant glioma patients considering IDH inhibitor therapy: A retrospective cohort study.

Journal: Neuro-oncology practice

Published: December 29, 2025

A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers.

Journal: Frontiers in molecular biosciences

Published: December 15, 2025

Vorasidenib and low-grade glioma: INDIGO incremental insights.

Journal: Neuro-oncology

Published: December 08, 2025

Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers.

Journal: EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]

Published: November 27, 2025

Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas.

Journal: Annual review of pathology

Published: November 18, 2025

Comparing Isocitrate Dehydrogenase Inhibitors with Procarbazine, Lomustine, and Vincristine Chemotherapy for Oligodendrogliomas.

Journal: Cancers

Published: November 13, 2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma.

Journal: International journal of clinical oncology

Published: October 25, 2025

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.

Journal: Chemistry & biodiversity

Published: October 08, 2025